
    due to slow/insufficient accrual and principal investigator left the nih
  
['chronic graft vs. host disease', 'graft vs host disease', 'graft-versus-host disease']
['methoxsalen']

        -  INCLUSION CRITERIA:

          -  Age greater than or equal to18 years.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

          -  Subject must be also enrolled on an National Cancer Institute (NCI) allogeneic
             transplant protocol.

          -  Patients must agree to practice effective contraception (both male and female
             subjects, if the risk of conception exists)The effects of Extracorporeal Photopheresis
             (ECP) on the developing human fetus are unknown. For this reason and as well as other
             Methoxsalen used in this trial is in a class of agents that is known to be
             teratogenic, men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation, and for 4 months after the completion of study treatment. Should a
             woman become pregnant or suspect she is pregnant while her partner is participating in
             this study, she should inform her treating physician immediately.

        EXCLUSION CRITERIA:

          -  Any physical or mental condition that, in the opinion of the principal Investigator
             (PI), would cause the risk/benefit ratio of participation to be unacceptable.

          -  Inclusion of ECP in the treatment of any patient is contraindicated by any of the
             following:

          -  Unstable hemodynamics requiring vasopressors or other support measures not amenable to
             or medically appropriate for continuation during the procedure.

          -  Uncontrolled infection.

          -  Inability to maintain acceptable venous access.

          -  Uncontrolled or uncorrectable coagulopathy.

          -  Pregnant women are excluded from ECP because methoxsalen, an agent utilized for the
             study procedure, may cause fetal harm. Because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with
             methoxsalen, breastfeeding should be discontinued if the mother is treated with
             methoxsalen. Pregnancy will be evaluated prior to initiation of ECP.

          -  History of allergic or idiosyncratic/hypersensitivity reactions to 8-
             methoxypsoralen/psoralen compounds.

          -  History of a light-sensitive cutaneous disease

          -  Subjects with aphakia
      